BioSpace

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment. https://hubs.li/Q03cWJ3k0

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy. https://hubs.li/Q03cWJ460

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy. https://hubs.li/Q03cVxzf0

After withdrawing its nomination for Dave Weldon last week, the Trump administration is now reportedly considering Texas Republican Michael Burgess to head the CDC. https://hubs.li/Q03cVBhD0

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money. https://hubs.li/Q03cVzkn0

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge. https://hubs.li/Q03cVztF0

Elevation Oncology is cutting about 70% of its staff. Get the details on this and other workforce reductions in our layoff tracker. #layoffs #biopharma #biospace https://hubs.li/Q03cVrtT0

TC BioPharm is cutting about half of its staff. Get the details about this and other workforce reductions in our regularly updated layoff tracker. #layoffs #biopharma #biospace https://hubs.li/Q03cJQ7S0

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients. https://hubs.li/Q03cHF7m0

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra. https://hubs.li/Q03cJSRW0